Candel Therapeutics (CADL) Depreciation & Amortization (CF) (2020 - 2025)

Candel Therapeutics has disclosed Depreciation & Amortization (CF) across 6 years of filings, most recently posting $100000.0 for Q4 2025.

• Depreciation & Amortization (CF) for Q4 2025 came in at $100000.0, down 66.67% year-over-year; the trailing twelve-month figure through Dec 2025 was $745000.0 (down 25.5% YoY), and the FY2025 annual result was $800000.0, down 20.0% from the prior year.
• Depreciation & Amortization (CF) came in at $100000.0 for Q4 2025 at Candel Therapeutics, down from $200000.0 in the prior quarter.
• In the past five years, Depreciation & Amortization (CF) ranged from a high of $300000.0 in Q4 2023 to a low of $7000.0 in Q2 2021.
• The 5-year median for Depreciation & Amortization (CF) is $200000.0 (2022), against an average of $183650.0.
• Across the five-year window, Depreciation & Amortization (CF) soared 2866.67% in 2021 and sank 66.67% in 2025, its largest moves.
• Candel Therapeutics' Depreciation & Amortization (CF) stood at $178000.0 in 2021, then changed by 0.0% to $178000.0 in 2022, then surged by 68.54% to $300000.0 in 2023, then changed by 0.0% to $300000.0 in 2024, then slumped by 66.67% to $100000.0 in 2025.
• The last three Depreciation & Amortization (CF) figures came in at $100000.0 (Q4 2025), $200000.0 (Q3 2025), and $200000.0 (Q2 2025), per Business Quant data.